Minute Insight: Abbott’s Aveir VR To Take On Medtronic’s Micra In US Leadless Pacemaker Market
Executive Summary
The US FDA approved Aveir VR to treat significant bradycardia on 4 April. It is the world’s only leadless pacemaker with Abbott’s proprietary mapping capability that helps physicians correctly position the device inside the right ventricle.
You may also be interested in...
Cardio Catch-Up: Abbott Plans To Expand Pacemaker Market With Leadless Aveir DR
The FDA approved Abbott’s Aveir DR dual-chamber leadless pacemaker system, which will complement Abbott’s Aveir VR technology and help Abbott compete directly with Medtronic in the growing leadless cardiac rhythm management device market.
Minute Insight: Medtronic Counters Abbott With New Micra Leadless Pacemakers
About a month after it approved Abbott’s Aveir VR leadless pacemaker, the FDA approved two new models of Medtronic’s Micra leadless pacemaker.
Exec Chat: Abbott Bets On Modular And Leadless Devices To Be The Future Of Cardiac Rhythm Management
Medtech Insight interviewed Leonard Ganz, a veteran cardiac electrophysiologist who recently joined Abbott’s cardiac rhythm management business as its divisional vice president of medical affairs and chief medical officer.